Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$580.3m

Arvinas Valuation

Is ARVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ARVN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARVN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARVN?

Key metric: As ARVN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ARVN. This is calculated by dividing ARVN's market cap by their current revenue.
What is ARVN's PS Ratio?
PS Ratio1.3x
SalesUS$426.90m
Market CapUS$580.28m

Price to Sales Ratio vs Peers

How does ARVN's PS Ratio compare to its peers?

The above table shows the PS ratio for ARVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
ZVRA Zevra Therapeutics
15.2x35.34%US$532.6m
ELTP Elite Pharmaceuticals
7.9xn/aUS$639.8m
EOLS Evolus
2.1x21.72%US$597.7m
XERS Xeris Biopharma Holdings
3.4x15.79%US$760.7m
ARVN Arvinas
1.3x-8.54%US$580.3m

Price-To-Sales vs Peers: ARVN is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does ARVN's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

58 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
0.8x0.42%US$10.94b
PRGO Perrigo
0.8x2.25%US$3.74b
AMRX Amneal Pharmaceuticals
0.9x7.87%US$2.64b
BHC Bausch Health Companies
0.3x-0.47%US$2.61b
ARVN 1.3xIndustry Avg. 4.7xNo. of Companies58PS048121620+
58 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ARVN is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is ARVN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARVN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: ARVN is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARVN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.79
US$19.36
+148.54%
115.67%US$110.00US$8.00n/a18
Jul ’26US$7.63
US$19.36
+153.75%
115.67%US$110.00US$8.00n/a18
Jun ’26US$7.20
US$19.36
+168.90%
115.67%US$110.00US$8.00n/a18
May ’26US$7.23
US$31.22
+331.84%
94.34%US$110.00US$8.00n/a18
Apr ’26US$7.03
US$43.32
+516.16%
64.78%US$110.00US$10.00n/a19
Mar ’26US$17.70
US$60.70
+242.94%
29.30%US$110.00US$28.00n/a20
Feb ’26US$17.61
US$63.25
+259.17%
27.45%US$110.00US$28.00n/a20
Jan ’26US$19.17
US$63.25
+229.94%
27.45%US$110.00US$28.00n/a20
Dec ’25US$26.72
US$62.95
+135.58%
28.22%US$110.00US$28.00n/a19
Nov ’25US$26.90
US$63.61
+136.47%
28.77%US$110.00US$28.00n/a18
Oct ’25US$24.88
US$65.78
+164.38%
27.17%US$110.00US$30.00n/a18
Sep ’25US$26.16
US$65.78
+151.44%
27.17%US$110.00US$30.00n/a18
Aug ’25US$26.78
US$66.39
+147.90%
25.45%US$110.00US$38.00n/a18
Jul ’25US$25.98
US$68.44
+163.45%
23.10%US$110.00US$38.00US$7.6318
Jun ’25US$33.14
US$68.44
+106.53%
23.10%US$110.00US$38.00US$7.2018
May ’25US$32.48
US$69.89
+115.18%
23.13%US$110.00US$38.00US$7.2318
Apr ’25US$40.40
US$70.89
+75.47%
21.04%US$110.00US$49.00US$7.0318
Mar ’25US$47.30
US$70.61
+49.28%
21.60%US$110.00US$49.00US$17.7018
Feb ’25US$45.65
US$64.42
+41.12%
37.64%US$110.00US$20.00US$17.6119
Jan ’25US$41.16
US$60.72
+47.53%
42.47%US$110.00US$20.00US$19.1718
Dec ’24US$23.60
US$57.28
+142.70%
48.39%US$110.00US$20.00US$26.7218
Nov ’24US$15.98
US$60.38
+277.82%
38.80%US$95.00US$24.00US$26.9016
Oct ’24US$19.64
US$67.06
+241.46%
30.96%US$95.00US$27.00US$24.8816
Sep ’24US$27.85
US$69.11
+148.15%
31.82%US$110.00US$27.00US$26.1618
Aug ’24US$24.86
US$72.22
+190.52%
28.31%US$110.00US$27.00US$26.7818
Jul ’24US$24.82
US$70.05
+182.24%
31.10%US$110.00US$27.00US$25.9819
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
US$19.36
Fair Value
59.8% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 03:11
End of Day Share Price 2025/07/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arvinas, Inc. is covered by 31 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
null nullBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research